Here's your product review news in brief from the US last week: Another fresh wave of approvals came out of FDA, most notably the agency's backing of US WorldMeds LLC’ Lucemyra (lofexidine) as the first non-opioid indicated for the management of opioid withdrawal symptoms.
Also joining the novel product front was Amgen Inc. and Novartis AG's preventative migraine treatment Aimovig (erenumab-aooe), the first of the three calcitonin gene-related peptide receptor (CGRP) antagonists...